Investors in Protagonist Therapeutics Lose 74% in One Year
October 17, 2022
Trending News 🌧️
Protagonist Therapeutics ($NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral peptide drugs for use in the treatment of serious diseases. Unfortunately, investors in Protagonist Therapeutics have lost 74% over the last year. The stock has been hurt by disappointing clinical trial results, delays in commercializing its lead product candidate, and a string of insider selling.
In addition, several insiders have sold large blocks of stock over the past year, which has further pressured the stock. Given the challenges faced by the company, it is not surprising that investors have lost confidence in Protagonist Therapeutics.
Price History
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel, orally-active, small molecule drugs that target protein homeostasis for the treatment of serious and life-threatening diseases. The company’s stock has been on a roller coaster ride over the past year, and investors have lost 74% of their investment in the company. The news coverage of Protagonist Therapeutics has been mostly mixed, with some positive and some negative articles. On Thursday, the stock opened at $8.0 and closed at $8.3, up by 2.1% from the last closing price of $8.2.
VI Analysis
According to the company’s fundamentals, PROTAGONIST THERAPEUTICS has an intermediate health score of 5/10. This means that the company has the potential to safely ride out any economic crisis without the risk of bankruptcy. The company is classified as a ‘cheetah’, a type of company that achieved high revenue or earnings growth but is considered less stable due to lower profitability. For investors, PROTAGONIST THERAPEUTICS is a company with strong asset and growth potential, but weak dividend and profitability prospects.
However, given the company’s relatively strong health score, it may be a good long-term investment for those with a higher risk tolerance.
Summary
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a focus on developing oral peptide drugs. The company’s stock has lost 74% of its value over the past year, and many investors have lost faith in the company’s ability to successfully develop and commercialize its products. Despite this, Protagonist Therapeutics continues to attract some interest from investors, as it has a number of potentially promising products in its pipeline. However, given the current state of the stock, it seems that many investors are not willing to take the risk on Protagonist Therapeutics.
